CHinese pulmOnary Embolism Multimodality Imaging-artifiCial intelligencE Study
Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Observational
SUMMARY
The CHinese pulmOnary Embolism Multimodality Imaging-artifiCial intelligencE Study (CHOICE) is a prospective observational multi-center study that will collect imaging text data and raw data of patients with pulmonary embolism (PE) in China. By combining artificial intelligence technology, it aims to identify imaging markers to assist in early diagnosis, differential diagnosis, risk stratification, and prognosis assessment of PE.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 14
Healthy Volunteers: f
View:
• 14 Years and older
• Patients suspected of PE
Locations
Other Locations
China
China-Japan Frendship hospital
RECRUITING
Beijing
Contact Information
Primary
Min Liu, PhD
mikie0763@126.com
+86-10-84205056
Time Frame
Start Date: 2010-09-01
Estimated Completion Date: 2028-09-01
Participants
Target number of participants: 1500
Treatments
Acute pulmonary embolism cohort
1. Patients objectively confirmed acute symptomatic PE or PE with deep vein thrombosis (DVT)~2. PE was confirmed by CTPA, lung V/Q scan or pulmonary angiography.
Chronic thromboembolic pulmonary disease without pulmonary hypertension cohort
1. Patients with functional impairment despite 3 months of adequate anticoagulation therapy after APE.~2. CTPA/ pulmonary angiography or V/Q scan showed unresolved thrombi in the pulmonary vessels.~3. Without pulmonary hypertension at rest(mean pulmonary arterial pressure (mPAP) \<20 mmHg), as measured by right heart catheterization.
Chronic thromboembolic pulmonary hypertension cohort
1. Patients with functional impairment despite 3 months of adequate anticoagulation therapy~2. CTPA/ pulmonary angiography or V/Q scan showed unresolved thrombi in the pulmonary vessels.~3. With pulmonary hypertension at rest (mean pulmonary arterial pressure (mPAP) \>20 mmHg), as measured by right heart catheterization.
Other pulmonary vascular disease cohort
Patients diagnosed with other pulmonary vascular disease including Takayasu arteritis, pulmonary artery sarcoma, and fibrosing mediastinitis.
Related Therapeutic Areas
Sponsors
Leads: China-Japan Friendship Hospital